Suppr超能文献

在生发中心后恶性肿瘤的条件性小鼠模型中,MYC转基因的AID依赖性激活可诱发多发性骨髓瘤。

AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

作者信息

Chesi Marta, Robbiani Davide F, Sebag Michael, Chng Wee Joo, Affer Maurizio, Tiedemann Rodger, Valdez Riccardo, Palmer Stephen E, Haas Stephanie S, Stewart A Keith, Fonseca Rafael, Kremer Richard, Cattoretti Giorgio, Bergsagel P Leif

机构信息

Comprehensive Cancer Center, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA.

出版信息

Cancer Cell. 2008 Feb;13(2):167-80. doi: 10.1016/j.ccr.2008.01.007.

Abstract

By misdirecting the activity of Activation-Induced Deaminase (AID) to a conditional MYC transgene, we have achieved sporadic, AID-dependent MYC activation in germinal center B cells of VkMYC mice. Whereas control C57BL/6 mice develop benign monoclonal gammopathy with age, all VkMYC mice progress to an indolent multiple myeloma associated with the biological and clinical features highly characteristic of the human disease. Furthermore, antigen-dependent myeloma could be induced by immunization with a T-dependent antigen. Consistent with these findings in mice, more frequent MYC rearrangements, elevated levels of MYC mRNA, and MYC target genes distinguish human patients with multiple myeloma from individuals with monoclonal gammopathy, implicating a causal role for MYC in the progression of monoclonal gammopathy to multiple myeloma.

摘要

通过将激活诱导脱氨酶(AID)的活性错误引导至一个条件性MYC转基因,我们在VkMYC小鼠的生发中心B细胞中实现了散发性、AID依赖性的MYC激活。对照C57BL/6小鼠随着年龄增长会发展为良性单克隆丙种球蛋白病,而所有VkMYC小鼠都会进展为一种惰性多发性骨髓瘤,其具有与人类疾病高度特征性相关的生物学和临床特征。此外,用T细胞依赖性抗原进行免疫可诱导抗原依赖性骨髓瘤。与小鼠中的这些发现一致,更频繁的MYC重排、MYC mRNA水平升高以及MYC靶基因可将多发性骨髓瘤患者与单克隆丙种球蛋白病患者区分开来,这表明MYC在单克隆丙种球蛋白病进展为多发性骨髓瘤过程中起因果作用。

相似文献

2
Modeling multiple myeloma by AID-dependent conditional activation of MYC.
Cancer Cell. 2008 Feb;13(2):85-7. doi: 10.1016/j.ccr.2008.01.022.
4
Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice.
J Hematol Oncol. 2019 Jul 5;12(1):70. doi: 10.1186/s13045-019-0767-9.
7
Role of activation-induced cytidine deaminase in the progression of follicular lymphoma.
Cancer Sci. 2012 Mar;103(3):415-21. doi: 10.1111/j.1349-7006.2011.02186.x. Epub 2012 Jan 17.
8
Timing the initiation of multiple myeloma.
Nat Commun. 2020 Apr 21;11(1):1917. doi: 10.1038/s41467-020-15740-9.
9
AID-initiated DNA lesions are differentially processed in distinct B cell populations.
J Immunol. 2014 Dec 1;193(11):5545-56. doi: 10.4049/jimmunol.1401549. Epub 2014 Oct 22.

引用本文的文献

1
Enhancing plasmacytoid dendritic cell functionality with retinoic acid for improved multiple myeloma therapy.
Mol Ther Oncol. 2025 May 14;33(2):200992. doi: 10.1016/j.omton.2025.200992. eCollection 2025 Jun 18.
2
MYC alterations in multiple myeloma: Genetic insights and prognostic impact.
Neoplasia. 2025 Aug;66:101177. doi: 10.1016/j.neo.2025.101177. Epub 2025 May 14.
4
Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors.
J Immunother Cancer. 2025 Jan 4;13(1):e008979. doi: 10.1136/jitc-2024-008979.
5
Complement C3d enables cell-mediated immunity capable of distinguishing spontaneously transformed from nontransformed cells.
Proc Natl Acad Sci U S A. 2024 Dec 24;121(52):e2405824121. doi: 10.1073/pnas.2405824121. Epub 2024 Dec 18.
6
Immunocompetent mouse models of multiple myeloma.
Semin Hematol. 2025 Feb;62(1):50-57. doi: 10.1053/j.seminhematol.2024.11.003. Epub 2024 Nov 16.
7
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.
J Exp Clin Cancer Res. 2024 Nov 1;43(1):294. doi: 10.1186/s13046-024-03217-2.
8
Type I-conventional dendritic cells support the progression of multiple myeloma in the bone marrow.
Front Immunol. 2024 Oct 15;15:1444821. doi: 10.3389/fimmu.2024.1444821. eCollection 2024.
9
Recent advances in targeted drug delivery systems for multiple myeloma.
J Control Release. 2024 Dec;376:215-230. doi: 10.1016/j.jconrel.2024.10.003. Epub 2024 Oct 12.
10
B-cell intrinsic RANK signaling cooperates with TCL1 to induce lineage-dependent B-cell transformation.
Blood Cancer J. 2024 Aug 28;14(1):151. doi: 10.1038/s41408-024-01123-6.

本文引用的文献

1
ELECTROPHORETIC PATTERNS OF NORMAL AND PATHOLOGICAL HUMAN BLOOD SERUM AND PLASMA.
J Exp Med. 1939 Sep 30;70(4):399-413. doi: 10.1084/jem.70.4.399.
2
Non-transcriptional control of DNA replication by c-Myc.
Nature. 2007 Jul 26;448(7152):445-51. doi: 10.1038/nature05953. Epub 2007 Jun 27.
3
Role of AID in tumorigenesis.
Adv Immunol. 2007;94:245-73. doi: 10.1016/S0065-2776(06)94008-5.
4
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice.
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1616-20. doi: 10.1073/pnas.0610732104. Epub 2007 Jan 24.
5
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
Blood. 2007 Apr 15;109(8):3489-95. doi: 10.1182/blood-2006-08-040410. Epub 2007 Jan 5.
6
Myc translocations in B cell and plasma cell neoplasms.
DNA Repair (Amst). 2006 Sep 8;5(9-10):1213-24. doi: 10.1016/j.dnarep.2006.05.017. Epub 2006 Jul 11.
7
Stromal niches, plasma cell differentiation and survival.
Curr Opin Immunol. 2006 Jun;18(3):265-70. doi: 10.1016/j.coi.2006.03.004. Epub 2006 Apr 17.
8
Prevalence of monoclonal gammopathy of undetermined significance.
N Engl J Med. 2006 Mar 30;354(13):1362-9. doi: 10.1056/NEJMoa054494.
9
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. doi: 10.1073/pnas.0506580102. Epub 2005 Sep 30.
10
Maintained rules of development in a mouse B-cell tumor.
Leukemia. 2005 Jul;19(7):1278-80. doi: 10.1038/sj.leu.2403774.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验